JP2017509647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509647A5 JP2017509647A5 JP2016557982A JP2016557982A JP2017509647A5 JP 2017509647 A5 JP2017509647 A5 JP 2017509647A5 JP 2016557982 A JP2016557982 A JP 2016557982A JP 2016557982 A JP2016557982 A JP 2016557982A JP 2017509647 A5 JP2017509647 A5 JP 2017509647A5
- Authority
- JP
- Japan
- Prior art keywords
- activin
- item
- composition
- antibody
- gdf11
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969073P | 2014-03-21 | 2014-03-21 | |
| US61/969,073 | 2014-03-21 | ||
| US201462021923P | 2014-07-08 | 2014-07-08 | |
| US62/021,923 | 2014-07-08 | ||
| PCT/US2015/021880 WO2015143403A1 (en) | 2014-03-21 | 2015-03-20 | Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020077142A Division JP7154250B2 (ja) | 2014-03-21 | 2020-04-24 | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017509647A JP2017509647A (ja) | 2017-04-06 |
| JP2017509647A5 true JP2017509647A5 (enExample) | 2018-04-26 |
Family
ID=54145413
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557982A Withdrawn JP2017509647A (ja) | 2014-03-21 | 2015-03-20 | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| JP2020077142A Active JP7154250B2 (ja) | 2014-03-21 | 2020-04-24 | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020077142A Active JP7154250B2 (ja) | 2014-03-21 | 2020-04-24 | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160046690A1 (enExample) |
| EP (1) | EP3119418B1 (enExample) |
| JP (2) | JP2017509647A (enExample) |
| KR (2) | KR102520970B1 (enExample) |
| CN (1) | CN106659769A (enExample) |
| AU (3) | AU2015231022B2 (enExample) |
| CA (1) | CA2942954A1 (enExample) |
| MA (1) | MA39722A (enExample) |
| WO (1) | WO2015143403A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| RU2018145985A (ru) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| EP3212213B1 (en) | 2014-10-30 | 2021-04-28 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| DK3286206T3 (da) | 2015-04-22 | 2021-05-03 | Biogen Ma Inc | Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme |
| EP3370754A4 (en) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| EA201990226A1 (ru) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | Способы и композиции для лечения миелофиброза |
| CN109996817A (zh) * | 2016-09-15 | 2019-07-09 | 艾科赛扬制药股份有限公司 | 扭转原肠胚形成多肽及其用途 |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| SMT202400437T1 (it) | 2017-06-14 | 2024-11-15 | Celgene Corp | Metodi per trattare mielofibrosi associata a neoplasia mieloproliferativa e anemia |
| CN107828719B (zh) * | 2017-09-14 | 2020-05-19 | 暨南大学 | Gdf11在脂肪间充质干细胞成骨分化中的应用 |
| KR20250059538A (ko) | 2017-11-09 | 2025-05-02 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7510875B2 (ja) | 2018-01-12 | 2024-07-04 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 |
| EP3788065B1 (en) * | 2018-04-30 | 2025-08-27 | The Children's Hospital Of Philadelphia | Improving anemias by combining agents |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN115279392A (zh) * | 2020-01-20 | 2022-11-01 | 鲁达库尔公司 | 治疗trpv1活性介导疾病的药物组合物 |
| KR20230004515A (ko) | 2020-03-20 | 2023-01-06 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2023212296A1 (en) * | 2022-04-29 | 2023-11-02 | University Of Massachusetts | Selective rna-modulating agents |
| WO2025040002A1 (zh) * | 2023-08-21 | 2025-02-27 | 苏州炫景生物科技有限公司 | 靶向inhbe基因的双链寡核苷酸、缀合物、组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0610248A2 (pt) * | 2005-04-25 | 2010-06-08 | Pfizer | anticorpos contra miostatina, composição farmacêutica compreendendo os mesmos, linhas celulares que os produzem , moléculas de ácido nucleico codificantes dos mesmos bem como seus usos |
| US8128933B2 (en) * | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| LT3750552T (lt) * | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| MX385318B (es) * | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| CA2770822C (en) * | 2009-08-13 | 2020-03-24 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| EP3520805B1 (en) * | 2011-10-17 | 2021-03-10 | Acceleron Pharma Inc. | Compositions for treating myelofibrosis |
| WO2013164444A1 (en) * | 2012-05-03 | 2013-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation |
| JP6401172B2 (ja) * | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
-
2015
- 2015-03-20 KR KR1020227044659A patent/KR102520970B1/ko active Active
- 2015-03-20 MA MA039722A patent/MA39722A/fr unknown
- 2015-03-20 AU AU2015231022A patent/AU2015231022B2/en not_active Ceased
- 2015-03-20 EP EP15765863.4A patent/EP3119418B1/en active Active
- 2015-03-20 KR KR1020167029253A patent/KR20160127148A/ko not_active Ceased
- 2015-03-20 JP JP2016557982A patent/JP2017509647A/ja not_active Withdrawn
- 2015-03-20 CA CA2942954A patent/CA2942954A1/en active Pending
- 2015-03-20 CN CN201580024704.5A patent/CN106659769A/zh active Pending
- 2015-03-20 WO PCT/US2015/021880 patent/WO2015143403A1/en not_active Ceased
- 2015-03-20 US US14/664,651 patent/US20160046690A1/en not_active Abandoned
-
2020
- 2020-04-24 JP JP2020077142A patent/JP7154250B2/ja active Active
- 2020-07-02 US US16/919,377 patent/US20210155672A1/en not_active Abandoned
-
2021
- 2021-01-19 AU AU2021200301A patent/AU2021200301A1/en not_active Abandoned
-
2023
- 2023-08-23 AU AU2023219885A patent/AU2023219885A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509647A5 (enExample) | ||
| JP6242847B2 (ja) | 血管増殖性疾患の治療 | |
| JP2017523140A5 (enExample) | ||
| US8426562B2 (en) | Methods and compositions for modulating tumor cell activity | |
| CN111499747B (zh) | 一种抗cd73单克隆抗体及其应用 | |
| JP2017516756A5 (enExample) | ||
| TR201808018T4 (tr) | Anti-B7-H3 antikoru. | |
| AU2011201436A1 (en) | Inhibitors of angiopoietin-like 4 protein, combinations, and their use | |
| JP2016508984A5 (enExample) | ||
| US10106601B2 (en) | Inhibition of PLGF to treat philadelphia chromosome positive leukemia | |
| WO2009116670A1 (ja) | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 | |
| JP2015516370A5 (enExample) | ||
| CN103561761A (zh) | 用于使用抗-整合素改善抗血管生成疗法的方法和组合物 | |
| US9963514B2 (en) | BAG3 receptor binding molecules for use as a medicament | |
| Eleftheriou et al. | Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling | |
| CA2762446C (en) | Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis | |
| WO2021140173A1 (en) | Methods and uses for treating fibrotic solid tumors with bags inhibitors | |
| Liu et al. | Potential role of axonal chemorepellent Slit2 in modulating adventitial inflammation in a rat carotid artery balloon injury model | |
| Hyde et al. | Finding New Partnerships: The Function of Individual Extracellular Receptor Domains in Angiogenic Signalling by VEGF Receptors | |
| Münch et al. | The dimeric platelet collagen receptor GPVI-Fc reduces | |
| NZ616809B2 (en) | Anti-b7-h3 antibody |